Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

00:00

Septobiprols - What's Next?

The numbers on patients with elevated vancoma mysees, I thought were very intriguing. And I think currently that's probably a place we're all looking to septariline more than dapto in those kinds of patients already. So, all in all, very exciting data and kudos to the authors. Rachel, do you want to guide us through the next exciting late breaking trial? This next study is Inhale WP3.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app